Company Profile
Alnylam Pharmaceuticals, Inc. Stock Price, News & Catalysts
- Ticker:
- ALNY
- Exchange:
- NASDAQ
- Sector:
- Nucleic Acid Drugs
- Location:
- Cambridge, Massachusetts
Stock performance
231.18 USD (-6.31%)
Close
Last updated: October 1, 2026
38.2B USD
Market cap
Why the stock is moving
As of Oct 1, 2026, ALNY closed down 6.31% at $231.18. No new same-company headline was identified in the current news window.
Company overview
RNA Interference Therapeutics Leader
Alnylam Pharmaceuticals develops medicines that use RNA interference to silence disease-causing genes. Its platform is designed to achieve durable reduction of specific proteins through infrequent subcutaneous or intravenous dosing, with programs spanning rare, cardiometabolic, and neurological diseases.
Transthyretin Amyloidosis Franchise
The company's largest franchise is built around AMVUTTRA and ONPATTRO for transthyretin-mediated amyloidosis. AMVUTTRA is positioned across both polyneuropathy and cardiomyopathy manifestations of ATTR, giving Alnylam a broad commercial presence in a progressive systemic disease.
Commercial Rare-Disease Portfolio
Alnylam also markets GIVLAARI for acute hepatic porphyria and OXLUMO for primary hyperoxaluria type 1. These products demonstrate the platform's ability to address liver-expressed genetic targets and support a specialized commercial model centered on diagnosis, patient identification, and long-term treatment.
Partnered Medicines and Economics
The company receives royalties from partnered RNAi medicines, including Leqvio, and collaborates with large pharmaceutical companies on development programs such as zilebesiran for hypertension. This structure allows Alnylam to retain selected products while using partners to reach broader primary-care and global markets.
Expanding Pipeline Beyond the Liver
Pipeline programs include ALN-6400 for bleeding disorders, mivelsiran for neurological disease, ALN-HTT02 for Huntington's disease, and ALN-2232 for obesity and weight management. New delivery approaches are intended to extend RNAi into the central nervous system and other tissues beyond the liver.
Future catalysts
- Presentation of Phase 1 ALN-HTT02 data in Huntington's disease at the 2026 European Huntington's Disease Network meeting.
- Phase 1 clinical results for ALN-6400 in healthy volunteers during 2026.
- Phase 1 clinical results for ALN-2232 in obesity and weight management during 2026.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Alnylam Pharmaceuticals, Inc. (ALNY)?
Alnylam Pharmaceuticals, Inc. (ALNY) most recently closed at 231.18 USD, a -6.31% move versus the previous session.
What is the market cap of Alnylam Pharmaceuticals, Inc. (ALNY)?
Alnylam Pharmaceuticals, Inc. currently has a market capitalization of 38.2B USD on BioPharmSignal.
What does Alnylam Pharmaceuticals, Inc. do?
RNA Interference Therapeutics Leader Alnylam Pharmaceuticals develops medicines that use RNA interference to silence disease-causing genes. Its platform is designed to achieve durable reduction of specific proteins through infrequent subcutaneous or intravenous dosing, with programs spanning rare, cardiometabolic, and neurological diseases. Transthyretin...
On which exchange is ALNY stock listed?
Alnylam Pharmaceuticals, Inc. (ALNY) is associated with NASDAQ, Cambridge, Massachusetts, Nucleic Acid Drugs.
What is ALN-6400?
Phase 1 clinical results for ALN-6400 in healthy volunteers during 2026.
Which conditions is Alnylam Pharmaceuticals, Inc. targeting with ALN-6400?
Alnylam Pharmaceuticals, Inc. is associated with metabolic disease, obesity, genetic disease based on its company overview and current catalyst commentary.
How does Alnylam Pharmaceuticals, Inc. describe recent progress with ALN-6400?
Phase 1 clinical results for ALN-6400 in healthy volunteers during 2026.
What is ALN-HTT02?
Expanding Pipeline Beyond the Liver Pipeline programs include ALN-6400 for bleeding disorders, mivelsiran for neurological disease, ALN-HTT02 for Huntington's disease, and ALN-2232 for obesity and weight management.